Disease relevance of L 689502

• Dose-dependent toxicokinetics of L-689,502, a potent human immunodeficiency virus protease inhibitor, in rats and dogs [1].
• Extracts of culture broths were examined for the production of metabolites of L-689,502 that could inhibit HIV-1 protease activity [2].
• Microbial biotransformations of L-689,502 by cultures belonging to the genus Streptomyces sp. were performed [2].
• Oral administration of the HIV protease inhibitor L-689,502 caused cholestasis and hepatocyte injury in rats and dogs [3].

High impact information on L 689502

• The effect of dose on the elimination kinetics of L-689,502 was studied in rats and dogs [1].
• One culture, MA 6804 (Streptomyces lavendulae, ATCC 55095), produced L-694,746 that, while being structurally related to L-689,502, is a novel metabolite and a potent inhibitor of HIV-1 protease [2].
• We examined the effect of an inhibitor of the viral protease, L-689,502, on virus production by monocyte-derived macrophages infected with HIV-1BaL [4].

Chemical compound and disease context of L 689502

• Inhibition of human immunodeficiency virus type-1 replication in macrophages and H9 cells by free or liposome-encapsulated L-689,502, an inhibitor of the viral protease [4].

Anatomical context of L 689502

• Histological examination of perfusion-fixed livers 30 min after L-689,502 administration revealed periportal changes including hepatocyte vacuolation and occasional single cell necrosis [3].

Associations of L 689502 with other chemical compounds

• Moreover, pretreatment of rats with L-689,502 resulted in a significant decrease in the elimination kinetics of antipyrine and diflunisal, as well as of L-689,502 itself [1].

References